Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Depreciation Expense (2016 - 2020)

Historic Depreciation Expense for Ani Pharmaceuticals (ANIP) over the last 9 years, with Q4 2020 value amounting to $1.3 million.

  • Ani Pharmaceuticals' Depreciation Expense rose 833.33% to $1.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.9 million, marking a year-over-year increase of 652.17%. This contributed to the annual value of $7.4 million for FY2024, which is 133.33% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Depreciation Expense of $1.3 million as of Q4 2020, which was up 833.33% from $1.2 million recorded in Q3 2020.
  • Ani Pharmaceuticals' Depreciation Expense's 5-year high stood at $1.3 million during Q4 2020, with a 5-year trough of $200000.0 in Q1 2016.
  • Over the past 5 years, Ani Pharmaceuticals' median Depreciation Expense value was $500000.0 (recorded in 2018), while the average stood at $680000.0.
  • Its Depreciation Expense has fluctuated over the past 5 years, first changed by 0.0% in 2016, then soared by 30000.0% in 2019.
  • Over the past 5 years, Ani Pharmaceuticals' Depreciation Expense (Quarter) stood at $200000.0 in 2016, then surged by 50.0% to $300000.0 in 2017, then surged by 166.67% to $800000.0 in 2018, then surged by 50.0% to $1.2 million in 2019, then rose by 8.33% to $1.3 million in 2020.
  • Its Depreciation Expense was $1.3 million in Q4 2020, compared to $1.2 million in Q3 2020 and $1.2 million in Q2 2020.